论文部分内容阅读
SAg是近十年来才兴起的一个科目。与普通Ag相较,主要区别在于前者免疫功效有赖于保持其蛋白质的完整性,对T细胞的激活机制非常独特,并且激活力度非常强大———只需极微量的SAg即可刺激大量T细胞增殖并诱导产生多种细胞因子和细胞毒性,从而引发好、坏及以至极坏的不同生理或病理结果。金葡菌产生的SAg至今已知有两种,其中尤以SE最具代表性,研究的比较深入,了解的也比较透彻。本文除对SE和SAg近年来国外的进展情况作一简介外,着重引述瑞典学者于1994年底在德国细菌学杂志的一期增刊上发表的关于利用SE作为开发抗癌制剂所依据的理论基础而进行的一系列的开发性研究。
SAg is a subject that emerged in the last ten years. The main difference compared with normal Ag is that the former’s immune function depends on maintaining the integrity of its protein, its unique mechanism of activation of T cells, and its activation is very strong --- it can stimulate a large number of T cells with a very small amount of SAg Proliferate and induce the production of a variety of cytokines and cytotoxicities that trigger different physiological or pathological consequences of good, worse, and even worse. So far, there are two kinds of SAg produced by Staphylococcus aureus, among which SE is the most representative, the research is more thorough and the understanding is also quite thorough. In addition to a brief introduction of the progress of SE and SAg abroad in recent years, this article focuses on the theoretical basis on which SE was used to develop anti-cancer preparations by Swedish scholars at the end of 1994 in the first issue of the German Journal of Bacteriology A series of developmental research conducted.